Tetracosactide

• A 2-stage, Adaptive, Randomised, Double-blind, Placebo-controlled, Multicentre Study to Evaluate Dose and Treatment Effect of Pentosan Polys… Not authorised
  2022-500228-31-00 Phase II/III 1 country Paradigm Biopharmaceuticals (USA) Inc.
• Long-term neuropsychologic outcome of pre-emptive mTOR inhibitor treatment in children with tuberous sclerosis complex (TSC) under 4 months … Recruiting
  2022-502332-39-00 Phase II 2 countries Heidelberg University Hospital AöR
• A Trial to Evaluate EP 104GI in Adults with Eosinophilic Esophagitis (EoE) (RESOLVE) Recruiting
  2024-516689-13-00 Phase I/II 1 country Eupraxia Pharmaceuticals Inc.
• MLS-101-901: An Open-Label Extension Study to Assess the Long-Term Safety, Efficacy, and Tolerability of Lorundrostat in Subjects with Hyper… Ended
  2023-508670-28-00 Phase III 8 countries Mineralys Therapeutics Inc.
• MLS-101-301: A Randomized, Double-Blind, Placebo Controlled, Parallel Arm, Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of … Ended
  2023-506425-12-00 Phase III 8 countries Mineralys Therapeutics Inc.
• A 2-stage, Adaptive, Randomised, Double-blind, Placebo-controlled, Multicentre Study to Evaluate Dose and Treatment Effect of Pentosan Polys… Ended
  2022-500228-31-01 Phase II/III 3 countries Paradigm Biopharmaceuticals (USA) Inc.
• Hydrocortisone and Fludrocortisone for Critical Illness-related Corticosteroid Insufficiency Ended
  2024-516021-32-00 Phase III 1 country Assistance Publique Hopitaux De Paris

Showing 1–7 of 7 trials